Background & aim: Dyslipidemia, characterized by hyper-cholesterolemia and hypertriglyceridemia, is a central component of metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis. While being highly instrumental in drug development, preclinical models of MASH often fail to recapitulate a human-like lipoprotein profile. To enhance…
Background & aim: Histopathological fibrosis staging is a key endpoint in preclinical drug development for MASH. However, the MASH CRN (Kleiner) system assigns one global stage per biopsy, potentially obscuring subtle treatment-related collagen remodelling and tissue heterogeneity. We developed an…
Background & aim: Menopause is associated with significant health changes and a broad range of symptoms, including adverse changes in body composition and metabolism and an increased risk of osteoporosis. Estradiol (E2)-based hormone replacement therapy effectively alleviates several menopausal symptoms…
Background & aim: Aims: Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function…
Background & aim: Conventional methods for assessing skeletal muscle remodelling, including lean mass, muscle weight, and histology, lack the spatial resolution and sensitivity to capture three-dimensional muscle architecture. Here, we developed a scalable, non-destructive, AI-enabled light-sheet fluorescence microscopy (LSFM) platform…
Background & aim: Efficient delivery of anti-β-amyloid (Aβ) antibodies across the blood–brain barrier (BBB) remains a central challenge in Alzheimer’s disease (AD) therapy. Therapeutic Aβ-targeted antibodies engineered for receptor-mediated transcytosis display improved brain exposure and therapeutic efficacy, yet their brain-wide…
Background & aim: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1RA effects on neuroinflammation remain poorly…
Background & aim: Chronic myocardial injury over weeks to months drives cellular hypertrophy and extracellular matrix remodeling, culminating in heart failure with preserved ejection fraction (HFpEF). Traditional 2D histological sectioning may miss or misrepresent the true spatial heterogeneity of localized…
